Biliary CA 19-9 Values Correlate with the Risk of Hepatic Metastases in Patients with Adenocarcinoma of the Pancreas

Journal of Gastrointestinal Surgery

Volumn 2, Issue 1, 1998, Pages 28-35

  Montgomery, Richard C ^a   Hoffman, John P ^a   Ross, Eric A ^a   Riley, Lee B ^a   Ridge, John A ^a   Eisenberg, Burton L ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; FORECASTING; HUMAN; IMMUNOLOGY; LIVER TUMOR; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PERITONEUM TUMOR; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE; CA-19-9 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 0031598832     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(98)80100-5     Document Type: Article

References (21)

1. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Mol Genet 1979;5:957-971.
2. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroentrol 1990;85:350-355.
3. Glenn J, Steinberg WM, Kurtzman SH, Steinberg S, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462-468.
4. Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R, Pedrazzoli S. CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993;52:137-141.
5. Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, Ferrari AM, Di Carlo V. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987;60:2428-2431.
6. Safi F, Schlosser W, Kolb G, Berger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106-112.
7. Pohl AL. Surveillance of cancer patients with tumor markers. J Tumor Marker Oncol 1987;2:1-14.
8. Johnstone PA, Sindelar WF. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: Correlations of a clinical trial. Int J Radiat Oncol 1993;27:831-834.
9. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer - Local or hepatic? Hepatogastroenterology 1993;40:384-387.
10. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993;72:2118-2123.
11. Satake K, Chung Y, Umeyama K, Takeuchi T, Kim Y. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. Cancer 1991;68:149-152.
12. American Joint Committee on Cancer. Exocrine Pancreas. In Manual for Staging of Cancer, 4th ed. Philadelphia: JB Lippincott, 1992, pp 109-111.
13. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996;46:5-27.
14. Wanabe T, Miyashita T, Ohshio G, et al. Small carcinoma of the pancreas. Clinical and pathologic evaluation in 17 patients. Cancer 1988;62:135.
15. Nagar H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986;204:65.
16. Haglund C, Lindgren J, Roberts PJ, Nordling S. Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer 1986;53:189-195.
17. Hagland C, Roberts PJ, Kuusela P, Scheinin TM, Makela O, Jalanko H. Evaluation of CA 19-9 as a serum tumor marker in pancreatic cancer. Br J Cancer 1986;53:197-202.
18. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-1225.
19. Willett CG, Daley WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996;172:350-352.
20. Lundin J, Roberts PJ, Kuusela P, Haglund C. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res 1995;15:2181-2186.
21. Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, Nakamori S, Hiratsuka M, Imaoka S. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastases after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994; 168:361-364.